In a patient with an A1c of 13.1% on glipizide 10 mg extended‑release daily and premixed insulin 70/30 (24 units twice daily), which additional medication should be added to lower the A1c?

Add a GLP-1 Receptor Agonist to Achieve Target A1c

For a patient with A1c 13.1% on glipizide 10 mg ER daily and premixed insulin 70/30 (24 units twice daily), the most effective medication to add is a GLP-1 receptor agonist such as dulaglutide (Trulicity) or semaglutide, which will provide an additional 1.0–2.0% A1c reduction while minimizing hypoglycemia and promoting weight loss. 1

---

Why GLP-1 Receptor Agonists Are the Priority Addition

Superior Glycemic Efficacy in Severe Hyperglycemia

• GLP-1 receptor agonists lower A1c by 1.0–2.0% when added to existing therapy, substantially more than other oral agents (which typically reduce A1c by 0.7–1.0%). 1
• In patients with A1c ≥9%, GLP-1 RAs are explicitly recommended before further insulin intensification because they provide potent glucose lowering without the weight gain and hypoglycemia associated with escalating insulin doses. 1
• The 2025 ADA guidelines state that when basal insulin has been optimized but A1c remains elevated, adding a GLP-1 RA is preferred over adding prandial insulin for most patients. 1

Cardiovascular and Renal Protection

• GLP-1 RAs with proven cardiovascular benefit (semaglutide, dulaglutide, liraglutide) reduce major adverse cardiovascular events and should be prioritized in patients with established ASCVD or high cardiovascular risk. 1
• These agents also slow progression of chronic kidney disease and reduce albuminuria, making them particularly valuable in patients with diabetic complications. 1

Weight and Hypoglycemia Advantages

• Unlike insulin intensification, GLP-1 RAs promote weight loss (typically 2–5 kg) rather than weight gain, addressing a major barrier to insulin therapy. 1
• Hypoglycemia risk remains low with GLP-1 RAs because their glucose-lowering effect is glucose-dependent, unlike sulfonylureas or insulin. 1

---

Why NOT to Add Other Medications First

SGLT2 Inhibitors: Insufficient Glycemic Potency

• While SGLT2 inhibitors provide cardiovascular and renal benefits, they lower A1c by only 0.5–0.7%, which is inadequate for a patient with A1c 13.1%. 1
• SGLT2 inhibitors are best reserved for patients with heart failure, CKD, or established ASCVD after achieving better glycemic control with more potent agents. 1

Additional Sulfonylureas or DPP-4 Inhibitors: Contraindicated

• The patient is already on glipizide 10 mg ER (maximum effective dose), so adding another sulfonylurea or increasing the dose offers no benefit. 2, 3
• DPP-4 inhibitors should never be combined with GLP-1 RAs because they share the same mechanism (incretin pathway) and provide no additive glucose lowering. 1
• DPP-4 inhibitors alone lower A1c by only 0.5–0.8%, which is insufficient for this degree of hyperglycemia. 3

Metformin: Should Be Added But Is Not Sufficient Alone

• Metformin should be started immediately (if not contraindicated) at 1000 mg twice daily, as it is the foundational therapy for type 2 diabetes. 1
• However, metformin alone will lower A1c by only 1.0–1.5%, which is inadequate for an A1c of 13.1%. 1
• Metformin should be combined with a GLP-1 RA to achieve the necessary A1c reduction. 1

---

Practical Implementation: Adding a GLP-1 Receptor Agonist

Recommended GLP-1 RA Options

• Dulaglutide (Trulicity) 1.5 mg once weekly is the most convenient option, with proven cardiovascular benefit and A1c reductions of 1.1–1.5%. 4
• Semaglutide 0.5–1.0 mg once weekly provides even greater A1c reduction (1.5–2.0%) and weight loss, with superior cardiovascular outcomes. 1
• Oral semaglutide (Rybelsus) 7–14 mg daily is an alternative for patients who prefer oral therapy, though injectable formulations are more effective. 1

Dosing and Titration

• Start dulaglutide at 0.75 mg once weekly for 4 weeks to minimize gastrointestinal side effects, then increase to 1.5 mg weekly. 4
• For semaglutide, start at 0.25 mg weekly for 4 weeks, then escalate to 0.5 mg weekly; further increase to 1.0 mg weekly if needed after 4 weeks. 1
• Continue the current insulin regimen unchanged initially, then adjust insulin doses downward as glucose improves to prevent hypoglycemia. 1

Expected Outcomes

• A1c reduction of 1.5–2.0% is achievable within 3–6 months, bringing A1c from 13.1% to approximately 11.1–11.6%. 1, 4
• Weight loss of 2–5 kg is typical, which improves insulin sensitivity and may allow further insulin dose reduction. 1, 4
• Fasting glucose should improve by 30–50 mg/dL within 4–8 weeks of starting therapy. 4

---

Addressing the Current Insulin Regimen

Why Premixed Insulin 70/30 Is Suboptimal

• Premixed insulin (70/30) has a fixed ratio of basal and prandial insulin, which limits individualized dose adjustments and increases hypoglycemia risk. 5
• In hospitalized patients, premixed insulin causes hypoglycemia in 64% of cases compared to 24% with basal-bolus regimens, and this risk extends to outpatient settings. 5
• Premixed insulin is not recommended for initial therapy or for patients requiring flexible meal timing. 5

Transition to Basal-Bolus Therapy (If Needed)

• Once the GLP-1 RA is established and A1c improves, consider transitioning from premixed insulin to a basal-bolus regimen (e.g., insulin glargine once daily + rapid-acting insulin before meals). 1, 6
• Basal-bolus therapy provides superior individualization and lower hypoglycemia risk compared to premixed formulations. 5
• Calculate the total daily insulin dose from the current premixed regimen (24 units × 2 = 48 units/day), then allocate 50% as basal insulin (24 units glargine once daily) and 50% as prandial insulin (8 units rapid-acting before each meal). 6

Adjusting Insulin Doses After Adding GLP-1 RA

• Reduce the premixed insulin dose by 10–20% (e.g., from 24 units to 20 units twice daily) when starting the GLP-1 RA to prevent hypoglycemia. 1
• Monitor fasting and pre-meal glucose daily during the first 2–4 weeks, and further reduce insulin doses if glucose falls below 100 mg/dL. 1
• Do not discontinue insulin entirely; patients with A1c 13.1% require both basal insulin and a GLP-1 RA to achieve target glucose levels. 1

---

Role of Metformin and Discontinuing Glipizide

Start or Optimize Metformin

• Metformin 1000 mg twice daily (2000 mg total) should be added immediately unless contraindicated by renal impairment (eGFR <30 mL/min) or acute illness. 1
• Metformin reduces total insulin requirements by 20–30% and provides complementary glucose-lowering effects when combined with GLP-1 RAs and insulin. 1
• Do not discontinue metformin when adding a GLP-1 RA or intensifying insulin; it remains the foundational therapy. 1

Discontinue Glipizide

• Glipizide should be discontinued once the GLP-1 RA is started, as sulfonylureas increase hypoglycemia risk when combined with insulin and GLP-1 RAs. 1
• Glipizide provides minimal additional benefit at the current dose (10 mg ER daily) and contributes to weight gain. 2, 3

---

Monitoring and Follow-Up

Glucose Monitoring During Titration

• Check fasting glucose daily to guide insulin dose adjustments. 1
• Measure pre-meal glucose before each meal if transitioning to basal-bolus therapy. 1
• Reassess A1c every 3 months until stable control is achieved. 1

Hypoglycemia Management

• Treat glucose <70 mg/dL immediately with 15 grams of fast-acting carbohydrate, recheck in 15 minutes, and repeat if needed. 1
• Reduce insulin doses by 10–20% if unexplained hypoglycemia occurs. 1

Expected Timeline to Target A1c

• A1c should decrease by 1.5–2.0% within 3–6 months of adding the GLP-1 RA, bringing A1c from 13.1% to approximately 11.1–11.6%. 1, 4
• Further A1c reduction to <9% will require continued insulin titration and optimization of metformin. 1
• Achieving A1c <7% may take 6–12 months and will likely require basal-bolus insulin therapy in addition to the GLP-1 RA and metformin. 1

---

Common Pitfalls to Avoid

• Do not delay adding a GLP-1 RA in favor of escalating insulin doses alone, as this leads to weight gain, hypoglycemia, and suboptimal control. 1
• Do not add an SGLT2 inhibitor first when A1c is 13.1%, as its glycemic efficacy is insufficient for this degree of hyperglycemia. 1
• Do not continue glipizide after starting a GLP-1 RA, as it increases hypoglycemia risk without additional benefit. 1, 2, 3
• Do not discontinue metformin when adding a GLP-1 RA or insulin, as it provides essential insulin-sparing effects. 1
• Do not rely solely on premixed insulin without addressing post-prandial hyperglycemia with a GLP-1 RA or transitioning to basal-bolus therapy. 5